Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTGKNB4)

• DTT Name: Epidermal growth factor receptor (EGFR) DTT Info
• Gene Name: EGFR

Molecule-Related Drug & Molecule List

19 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25	Approved	[1]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[2]
Cetuximab	DMLNCE0	Colorectal cancer	2B91.Z	Approved	[3]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Epidermal growth factor	DMVONE6	Vulnerary	ND56.Z	Approved	[4]
Erlotinib	DMCMBHA	Adrenal gland neoplasm		Approved	[5]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[6]
HEGF	DMN0S1G	Diabetic foot ulcer	BD54	Approved	[7]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[8]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[9]
Necitumumab	DMKOJSN	Colorectal cancer	2B91.Z	Approved	[10]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[11]
Nitroglycerin	DMQ2491	Angina pectoris	BA40	Approved	[7]
Osimertinib	DMRJLAT	Non-small-cell lung cancer	2C25.Y	Approved	[12]
Panitumumab	DMQPD1F	Colorectal cancer	2B91.Z	Approved	[13]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[14]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[15]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[16]
Icotinib hydrochloride	DM5GFIK	Non-small-cell lung cancer	2C25.Y	Registered	[17]

65 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
A140	DMEAWJT	Head and neck cancer	2D42	Phase 3	[18]
Almonertinib	DMCHA27	Non-small-cell lung cancer	2C25.Y	Phase 3	[19]
ASP1929	DMR71ST	Head and neck cancer	2D42	Phase 3	[20]
CO-1686	DMWZ2TU	Lung cancer	2C25.0	Phase 3	[21]
DE-766	DM0GUV2	Gastric adenocarcinoma	2B72	Phase 3	[4]
EGF816	DMCMJRA	Non-small-cell lung cancer	2C25.Y	Phase 3	[22]
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[23]
Rindopepimut	DMP6IMQ	Brain cancer	2A00	Phase 3	[10]
SYM-004	DMOVEDH	Metastatic colorectal cancer	2B91	Phase 3	[24]
Zalutumumab	DM52QEZ	Head and neck cancer	2D42	Phase 3	[4]
Indium-111	DMC3794	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[25]
Varlitinib	DMDG8Q3	Metastatic biliary tract neoplasms	2C14-2C17	Phase 2/3	[26]
ABT-414	DMGUTPN	Glioblastoma multiforme	2A00.0	Phase 2	[27]
ABX-EGF	DM91U0R	N. A.	N. A.	Phase 2	[28]
ASP8273	DMHLXUY	Non-small-cell lung cancer	2C25.Y	Phase 2	[29]
BMS-599626	DMDPQV5	Solid tumour/cancer	2A00-2F9Z	Phase 2	[30]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[31]
CetuGEX	DMAWKSM	Solid tumour/cancer	2A00-2F9Z	Phase 2	[32]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[16]
Depatuxizumab	DM7GPMB	Glioblastoma of brain	2A00.00	Phase 2	[33]
HER1-VSSP vaccine	DMX6B95	Solid tumour/cancer	2A00-2F9Z	Phase 2	[34]
HM-78136B	DMZ3BER	HER2-positive breast cancer	2C60-2C65	Phase 2	[35]
Matuzumab	DM2458E	Gastric adenocarcinoma	2B72	Phase 2	[36]
MEHD-7945A	DMHOF7T	Colorectal cancer	2B91.Z	Phase 2	[26]
Pelitinib	DMIW453	Lymphoma	2A80-2A86	Phase 2	[37]
RM-1929	DMVU1R9	Head and neck cancer	2D42	Phase 2	[35]
Tarloxotinib	DMA7ISF	Non-small-cell lung cancer	2C25.Y	Phase 2	[38]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[39]
VATALANIB	DMY0UEQ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[23]
AFM24	DMFTZX0	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[40]
BDTX-189	DMODTX5	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[41]
CART-EGFR	DM3I267	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[42]
EGFR CART	DMDWCOF	Colorectal cancer	2B91.Z	Phase 1/2	[43]
EMB-01	DMCAUKW	Neoplasm	2A00-2F9Z	Phase 1/2	[44]
EMD 55900	DMMD10S	Glioma	2A00.0	Phase 1/2	[28]
SN-32793	DMEJT5Z	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[4]
Sym013	DMZM6I2	Epithelial ovarian cancer	2B5D	Phase 1/2	[33]
Sym015	DM9B7Z5	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[33]
TAK-186	DM6XL9A	Aggressive cancer	2A00-2F9Z	Phase 1/2	[45]
ZN-e4	DMLV4U1	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[46]
S-222611	DMQGH76	Malignant solid tumour	2C10-2F32	Phase 1b	[47]
AMG 595	DMJFKW3	Glioblastoma multiforme	2A00.0	Phase 1	[48]
Anti-EGFR CAR T	DMIVUX1	Glioma	2A00.0	Phase 1	[49]
Anti-HER3/EGFR DAF	DMDMNJ6	Metastatic epithelial tumour	2D60	Phase 1	[50]
AP32788	DMGDARN	Non-small-cell lung cancer	2C25.Y	Phase 1	[35]
AST-1306	DMD83WO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[51]
AZD9592	DMDPM67	Aggressive cancer	2A00-2F9Z	Phase 1	[52]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[53]
BIBX-1382	DM79XGM	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[54]
Cipatinib	DMJLNEF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
CLN-081	DM05R4C	Non-small-cell lung cancer	2C25.Y	Phase 1	[55]
CUDC-101	DM9ZOMD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[56]
CX-904	DMOOHDN	Colorectal cancer	2B91.Z	Phase 1	[57]
D2C7	DMIMK84	Glioblastoma of brain	2A00.00	Phase 1	[58]
EGFR806-specific CAR T cell	DM3AD65	Atypical teratoid/rhabdoid tumour	2A00.1Y	Phase 1	[59]
HER-2/HER-1 vaccine	DMXETUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
IMGN289	DMT9MHE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[60]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[61]
LY3164530	DM9RTXM	Advanced cancer	2A00-2F9Z	Phase 1	[62]
MCLA-158	DMF0O3X	Solid tumour/cancer	2A00-2F9Z	Phase 1	[63]
MM-151	DMXQHZC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]
MR1-1	DME7JFM	Brain cancer	2A00	Phase 1	[64]
PF-05230907	DM7GSZL	Nontraumatic intracerebral hemorrhage	8B00.4	Phase 1	[65]
SI-B001	DMDSFEB	Metastatic epithelial tumour	2D60	Phase 1	[66]
SYN004	DM0EZ69	Solid tumour/cancer	2A00-2F9Z	Phase 1	[33]

1 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrrolo[2,3-d]pyrimidine derivative 24	DMZQF9R	N. A.	N. A.	Patented	[67]

9 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PKI166	DMSQ794	Esophageal cancer	2B70	Discontinued in Phase 2	[68]
RG7160	DM5KJGB	Metastatic colorectal cancer	2B91	Discontinued in Phase 2	[69]
AZD4769	DMA3OWI	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[70]
PD-153035	DM7KJTI	Psoriasis vulgaris	EA90	Discontinued in Phase 1	[71]
TAK165	DMBE5OF	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[16]
AZD-9935	DMFE3CD	Solid tumour/cancer	2A00-2F9Z	Terminated	[74]
CGP-52411	DMIWUFC	Solid tumour/cancer	2A00-2F9Z	Terminated	[75]
CGP-53353	DM9VDZP	N. A.	N. A.	Terminated	[76]
Heparin-EGF-like factor	DMMXG2I	Gastrointestinal disease	DE2Z	Terminated	[77]

2 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
111In-hEGF	DM9TQDE	Breast cancer	2C60-2C65	Preclinical	[72]
EGFR/IGFR tandem adnectin	DMZ3YP6	Solid tumour/cancer	2A00-2F9Z	Preclinical	[73]

104 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine	DMHLF2S	Discovery agent	N.A.	Investigative	[78]
(3-Bromo-phenyl)-quinazolin-4-yl-amine	DMMIPZ8	Discovery agent	N.A.	Investigative	[79]
(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin	DM81JRF	Discovery agent	N.A.	Investigative	[80]
(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate	DMA43NY	Discovery agent	N.A.	Investigative	[81]
10-hydroxy-18-methoxybetaenone	DM4R7X8	Discovery agent	N.A.	Investigative	[82]
2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile	DM4BFHR	Discovery agent	N.A.	Investigative	[83]
2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile	DMTC5Y9	Discovery agent	N.A.	Investigative	[83]
2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile	DMO97FR	Discovery agent	N.A.	Investigative	[81]
2-cyano-3-(3,4-dihydroxyphenyl)acrylamide	DMCN6PY	Discovery agent	N.A.	Investigative	[81]
2-methoxy-4-(2-nitrovinyl)phenol	DMEAVD2	Discovery agent	N.A.	Investigative	[81]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[84]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[84]
3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one	DMD4O6V	Discovery agent	N.A.	Investigative	[85]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[84]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[84]
3-Pyridin-4-yl-quinoline-6,7-diol	DME1TUK	Discovery agent	N.A.	Investigative	[86]
4-(2-nitroprop-1-enyl)benzene-1,2-diol	DMCHTI0	Discovery agent	N.A.	Investigative	[81]
4-(2-nitrovinyl)benzene-1,2-diol	DM62ZRE	Discovery agent	N.A.	Investigative	[81]
4-(2-nitrovinyl)phenol	DMPTVR2	Discovery agent	N.A.	Investigative	[81]
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline	DMNBLQ8	Discovery agent	N.A.	Investigative	[87]
4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline	DMK6JV7	Discovery agent	N.A.	Investigative	[87]
4-(3-Bromo-phenylamino)-quinazoline-6,7-diol	DM1Q5KV	Discovery agent	N.A.	Investigative	[79]
4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid	DMWBVMH	Discovery agent	N.A.	Investigative	[81]
4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline	DMLSGU1	Discovery agent	N.A.	Investigative	[88]
4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	DMN2TMS	Discovery agent	N.A.	Investigative	[89]
4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline	DMYUL9J	Discovery agent	N.A.	Investigative	[90]
4557W	DMLE0I7	Discovery agent	N.A.	Investigative	[91]
5,6-Bis-p-tolylamino-isoindole-1,3-dione	DM6A4LM	Discovery agent	N.A.	Investigative	[76]
5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide	DMB7R95	Discovery agent	N.A.	Investigative	[89]
6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline	DMI7FVJ	Discovery agent	N.A.	Investigative	[90]
6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline	DMFVT8A	Discovery agent	N.A.	Investigative	[90]
6,7-diethoxy-4-styrylquinazoline	DMVR4OW	Discovery agent	N.A.	Investigative	[90]
6,7-dimethoxy-4-(2-phenylethynyl)quinazoline	DMQTHV7	Discovery agent	N.A.	Investigative	[90]
6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline	DMKO8QT	Discovery agent	N.A.	Investigative	[90]
6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline	DMBI40Y	Discovery agent	N.A.	Investigative	[90]
6,7-dimethoxy-N-m-tolylquinazolin-4-amine	DMP8LXB	Discovery agent	N.A.	Investigative	[92]
6-chloro-N-(3-chlorophenyl)quinazolin-4-amine	DMPIFLA	Discovery agent	N.A.	Investigative	[93]
AFM-21	DM8U1IW	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
AG 112	DMDYS0L	Discovery agent	N.A.	Investigative	[94]
AG 9	DMSOUI0	Discovery agent	N.A.	Investigative	[94]
AG-213	DMT3ML6	Discovery agent	N.A.	Investigative	[88]
AG-538	DM9KIS8	Discovery agent	N.A.	Investigative	[81]
AGT-2000	DMP9QW0	Brain cancer	2A00	Investigative	[4]
AL-6802	DM3JNRC	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
Anti-EGFR humanized mabs	DMWLMV2	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
Anti-EGFR mab	DMW85FP	Discovery agent	N.A.	Investigative	[4]
ARX-AHD	DM15KLR	Breast cancer	2C60-2C65	Investigative	[4]
Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine	DMISHTB	Discovery agent	N.A.	Investigative	[79]
Benzyl-quinazolin-4-yl-amine	DMRW5J4	Discovery agent	N.A.	Investigative	[78]
Bmab-200	DM8AEQX	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
BPIQ-I	DMNHEUT	Discovery agent	N.A.	Investigative	[79]
CL-387785	DMLKFZC	Discovery agent	N.A.	Investigative	[92]
Cochliobolic acid	DMOUSWN	Discovery agent	N.A.	Investigative	[95]
EDP-13	DMLSMBI	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
EGFR inhibitor	DM7AYH4	Discovery agent	N.A.	Investigative	[96]
Epitinib	DM1C8FW	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
FHT-2107	DMH7LDX	Discovery agent	N.A.	Investigative	[4]
GI-3000	DMU92RC	Non-small-cell lung cancer	2C25.Y	Investigative	[4]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[97]
HKI-9924129	DM5LR2B	Gram-positive bacterial infection	1B74-1G40	Investigative	[98]
HM-61713B	DMNOFTX	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
HTS-00213	DMQ8ADE	Discovery agent	N.A.	Investigative	[92]
HTS-02876	DMVUTJ5	Discovery agent	N.A.	Investigative	[92]
HTS-05058	DM3F4IQ	Discovery agent	N.A.	Investigative	[96]
ICR 62	DMH4KGX	Discovery agent	N.A.	Investigative	[28]
IPS-01003	DM0T8ZU	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
LA22-radioimmunoconjugates	DMY6K2A	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
LAVENDUSTIN A	DMH3X06	Discovery agent	N.A.	Investigative	[99]
mabionHER2	DMJX2CS	Breast cancer	2C60-2C65	Investigative	[4]
MDP-01	DM8ZK12	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
MG-111	DMG56EU	Discovery agent	N.A.	Investigative	[100]
MT-062	DM5PD0G	Melanoma	2C30	Investigative	[4]
N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine	DMFWN5U	Discovery agent	N.A.	Investigative	[79]
N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine	DMUI8RC	Discovery agent	N.A.	Investigative	[101]
N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine	DMO56XY	Discovery agent	N.A.	Investigative	[78]
N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine	DMK674I	Discovery agent	N.A.	Investigative	[102]
N-(4-(phenylamino)quinazolin-6-yl)acrylamide	DMI74KM	N. A.	N. A.	Investigative	[103]
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide	DMEBGF1	Discovery agent	N.A.	Investigative	[104]
N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide	DMG6RTJ	Discovery agent	N.A.	Investigative	[104]
N4-(3-chlorophenyl)quinazoline-4,6-diamine	DM561Z7	Discovery agent	N.A.	Investigative	[105]
N4-(3-methylphenyl)-4,6-quinazolinediamine	DMDRYJ7	Discovery agent	N.A.	Investigative	[106]
NRC-2694	DMXP03H	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
ON-128	DMTNKBW	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
OSI-75	DM5IGN7	Discovery agent	N.A.	Investigative	[107]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[98]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[98]
PD-158780	DMQXYE9	Discovery agent	N.A.	Investigative	[102]
PD-168393	DMN8M5P	Discovery agent	N.A.	Investigative	[103]
PD182905	DMXLW4F	Discovery agent	N.A.	Investigative	[108]
PF 5208766	DMY45K1	Discovery agent	N.A.	Investigative	[109]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[110]
PMID8568816C56	DMG3ZD1	Discovery agent	N.A.	Investigative	[111]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[112]
RG-50810	DMUR9LM	Discovery agent	N.A.	Investigative	[81]
RM-6427	DM87Z3Y	Cryptosporidium infection	1A32	Investigative	[4]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[113]
RX-1792	DMKYNGE	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
SYM-011	DMKIDRY	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
TGF alpha	DMOX3AH	Cerebrovascular ischaemia	8B1Z	Investigative	[4]
Theliatinib	DMRVXFN	Solid tumour/cancer	2A00-2F9Z	Investigative	[4]
Tyrphostin ag-1478	DM87ZIH	Discovery agent	N.A.	Investigative	[85]
WHI-P154	DMYHWS1	Diffuse large B-cell lymphoma	2A81	Investigative	[114]
WZ-3146	DMBWUR0	Lung cancer	2C25.0	Investigative	[4]
YH013	DMQ0474	Aggressive cancer	2A00-2F9Z	Investigative	[115]

References

• [1] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [2] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [3] Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
• [5] Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
• [6] Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
• [7] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [8] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [9] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [10] Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
• [11] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [12] AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.
• [13] Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.
• [14] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [15] Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
• [16] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [17] Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.
• [18] Clinical pipeline report, company report or official report of Klus Pharma
• [19] Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918.
• [20] ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
• [21] Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.
• [22] Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
• [23] Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.
• [24] Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.
• [25] Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.
• [26] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [27] Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
• [28] Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.
• [29] Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
• [30] AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61.
• [31] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [32] Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.
• [33] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [34] Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
• [35] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [36] Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.
• [37] EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.
• [38] Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475.
• [39] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [40] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [41] Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
• [42] ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
• [43] ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
• [44] Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
• [45] Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186. J Immunother Cancer. 2022 Jun;10(6):e004336.
• [46] Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
• [47] Clinical pipeline report, company report or official report of Shionogi (2011).
• [48] AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.
• [49] ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
• [50] Company report (Biooncology)
• [51] AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.
• [52] Clinical pipeline report, company report or official report of AstraZeneca
• [53] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [54] Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
• [55] TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.
• [56] A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.
• [57] Clinical pipeline report, company report or official report of CytomX
• [58] Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142.
• [59] ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
• [60] World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
• [61] National Cancer Institute Drug Dictionary (drug id 596693).
• [62] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [63] Clinical pipeline report, company report or official report of Merus.
• [64] A Phase I Study of Immunotoxin, MR1-1. Duke University report.
• [65] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [66] Clinical pipeline report, company report or official report of SystImmune.
• [67] Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318.
• [68] Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.
• [69] GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.
• [70] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [71] EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.
• [72] A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
• [73] Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
• [74] WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
• [75] Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
• [76] Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
• [77] The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.
• [78] Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.
• [79] Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.
• [80] 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.
• [81] Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.
• [82] Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45.
• [83] Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.
• [84] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [85] Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.
• [86] 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
• [87] A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
• [88] Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.
• [89] Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.
• [90] Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.
• [91] Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5.
• [92] Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.
• [93] Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.
• [94] Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.
• [95] Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8.
• [96] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [97] Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.
• [98] Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
• [99] Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.
• [100] Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.
• [101] Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.
• [102] Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.
• [103] Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.
• [104] Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.
• [105] Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.
• [106] The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52.
• [107] Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
• [108] Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.
• [109] Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.
• [110] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [111] Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.
• [112] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [113] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [114] The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.
• [115] Clinical pipeline report, company report or official report of Biocytogen